Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.61 |
| ▸ | CFTR | P13569 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31017519 | 1.00 | GAA (0.61) | GAACFTRALDH1A1KDM4EMAPT | |
| SCHEMBL17822745 | 0.85 | GAA (0.66) | GAACFTRALDH1A1KDM4EMAPT | |
| SCHEMBL1403643 | 0.82 | GAA (0.72) | GAACFTRALDH1A1KDM4EMAPT | |
| SCHEMBL1277539 | 0.81 | CA12 (0.44) | GAACFTRALDH1A1KDM4EMAPT | |
| SCHEMBL7623605 | 0.81 | GAA (0.70) | GAACFTRALDH1A1KDM4EMAPT | |
| SCHEMBL9705197 | 0.81 | GAA (0.65) | GAACFTRALDH1A1KDM4EMAPT | |
| SCHEMBL6168887 | 0.81 | GAA (0.66) | GAACFTRALDH1A1KDM4EMAPT | |
| SCHEMBL31506855 | 0.79 | CYP46A1 (0.53) | GAACFTRALDH1A1KDM4EMAPT | |
| SCHEMBL166743 | 0.79 | CA12 (0.67) | GAACFTRALDH1A1KDM4EMAPT | |
| SCHEMBL27707943 | 0.79 | KDM4E (0.58) | GAAALDH1A1KDM4EMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | PRAZER THERAPEUTICS INC. (KR) | 2024-12-26 | — | — | US | disclosed |
| EP-4450490-A1 | NOVEL COMPOUND FOR DEGRADING TARGET PROTEIN OR POLYPEPTIDE BY USING POLYUBIQUITINATION | Prazer Therapeutics Inc. (KR) | 2024-10-23 | — | — | EP | disclosed |
| CN-118382620-A | Novel compounds for degrading target proteins or polypeptides by multiple ubiquitination | 普瑞泽治疗公司 | 2024-07-23 | — | — | CN | disclosed |
| WO-2023113457-A1 | NOVEL COMPOUND FOR DEGRADING TARGET PROTEIN OR POLYPEPTIDE BY USING POLYUBIQUITINATION | (주)프레이저테라퓨틱스 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023113456-A1 | NOVEL COMPOUND FOR DEGRADING TARGET PROTEIN OR POLYPEPTIDE BY USING POLYUBIQUITINATION | (주)프레이저테라퓨틱스 | 2023-06-22 | — | — | WO | disclosed |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20220119392-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2022-04-21 | — | — | US | disclosed |
| WO-2015197028-A1 | COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015197028-A1 | COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | ADRM1, SUMO1, SUMO2 | GAA 557/4885CFTR 3621/4885ALDH1A1 3989/4885 |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | GAA 2610/4885CFTR 2108/4885ALDH1A1 1219/4885 |
| US-20220119392-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | GAA 2610/4885CFTR 2108/4885ALDH1A1 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.